Petra Andrén

Carina Biotech An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing. We are working to… 1. Expand the clinical indications for T cell therapies 2. Improve the commercial viability of T cell therapies by developing supporting technologies that make T cell therapies more effective or economically viable Headquartered in Adelaide, South Australia, Carina has strong T cell R&D capability across a network of research providers and collaborators including leading scientists at the UniSA, the Womens & Childrens Hospital in Adelaide, the University of Adelaide, the Royal Prince Alfred Hospital in NSW and the Seattle Childrens Hospital in the United States.

Accelerator: https://www.startmate.com/accelerator/program First Believers: https://www.startmate.com/first-believers/program We back the most ambitious founders in ANZ 🚀 From founders who are pre-revenue to scaling globally, Startmate is the epicentre of startup ambition. We run programs for founders, operators and investors, fuelled by a community that believes big. You bring the ambition. We’ll bring the jet fuel ✈️

We’re an independent statutory board of entrepreneurs, investors, researchers and educators. Between us we have extensive local and global experience in industry, innovation, science and research. We aim to support and enhance Australia’s innovation, science and research system by: - advising the Australian Government about innovation, science and research matters - monitoring and overseeing a number of innovation programs under several sub-committees - coordinating the government’s investment in innovation, science and research - reviewing Australia’s innovation and science system performance - stimulating public discussion and debate about innovation and science Were supported by the Office of Industry Innovation and Science Australia.

Carina Biotech An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing. We are working to… 1. Expand the clinical indications for T cell therapies 2. Improve the commercial viability of T cell therapies by developing supporting technologies that make T cell therapies more effective or economically viable Headquartered in Adelaide, South Australia, Carina has strong T cell R&D capability across a network of research providers and collaborators including leading scientists at the UniSA, the Womens & Childrens Hospital in Adelaide, the University of Adelaide, the Royal Prince Alfred Hospital in NSW and the Seattle Childrens Hospital in the United States.

We believe traditional hurdles to innovation are being destroyed empowering start-ups to innovate at unprecedented speed and scale. Combining deep market knowledge and sector expertise with a passion for building groundbreaking companies, we work alongside companies to tackle the challenges of the global food economy. We operate out of Amsterdam, Boston and London with a global outlook. Backed by leading LPs, we look to catalyze transformation with a world class network, financial flexibility and patient capital.

Accelerator: https://www.startmate.com/accelerator/program First Believers: https://www.startmate.com/first-believers/program We back the most ambitious founders in ANZ 🚀 From founders who are pre-revenue to scaling globally, Startmate is the epicentre of startup ambition. We run programs for founders, operators and investors, fuelled by a community that believes big. You bring the ambition. We’ll bring the jet fuel ✈️

Tattarang is the private investment group of Andrew and Nicola Forrest. We’re proudly Australian and invest across a wide variety of sectors and asset classes, including in real assets, public and private markets. We believe in using our capital as a force for good.